OS Therapies (OSTX) Competitors $1.62 -0.11 (-6.36%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$1.58 -0.04 (-2.41%) As of 05:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OSTX vs. CRDF, MDWD, EPRX, SOPH, INBX, YMAB, ACIU, VOR, SCPH, and IMABShould you be buying OS Therapies stock or one of its competitors? The main competitors of OS Therapies include Cardiff Oncology (CRDF), MediWound (MDWD), Eupraxia Pharmaceuticals (EPRX), SOPHiA GENETICS (SOPH), Inhibrx Biosciences (INBX), Y-mAbs Therapeutics (YMAB), AC Immune (ACIU), Vor Biopharma (VOR), scPharmaceuticals (SCPH), and I-Mab (IMAB). These companies are all part of the "pharmaceutical products" industry. OS Therapies vs. Its Competitors Cardiff Oncology MediWound Eupraxia Pharmaceuticals SOPHiA GENETICS Inhibrx Biosciences Y-mAbs Therapeutics AC Immune Vor Biopharma scPharmaceuticals I-Mab OS Therapies (NYSE:OSTX) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation. Is OSTX or CRDF more profitable? OS Therapies has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,308.50%. OS Therapies' return on equity of 0.00% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets OS TherapiesN/A N/A -569.57% Cardiff Oncology -8,308.50%-76.45%-62.85% Does the media refer more to OSTX or CRDF? In the previous week, Cardiff Oncology had 1 more articles in the media than OS Therapies. MarketBeat recorded 5 mentions for Cardiff Oncology and 4 mentions for OS Therapies. Cardiff Oncology's average media sentiment score of 0.72 beat OS Therapies' score of 0.17 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OS Therapies 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiff Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer OSTX or CRDF? OS Therapies presently has a consensus target price of $18.00, indicating a potential upside of 1,011.11%. Cardiff Oncology has a consensus target price of $11.70, indicating a potential upside of 196.95%. Given OS Therapies' stronger consensus rating and higher possible upside, analysts clearly believe OS Therapies is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40Cardiff Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has preferable valuation & earnings, OSTX or CRDF? OS Therapies has higher earnings, but lower revenue than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than OS Therapies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOS TherapiesN/AN/A-$7.79M-$0.86-1.88Cardiff Oncology$680K385.48-$45.43M-$0.92-4.28 Do insiders and institutionals believe in OSTX or CRDF? 16.3% of Cardiff Oncology shares are held by institutional investors. 13.8% of OS Therapies shares are held by company insiders. Comparatively, 7.7% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryOS Therapies beats Cardiff Oncology on 9 of the 15 factors compared between the two stocks. Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OSTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OSTX vs. The Competition Export to ExcelMetricOS TherapiesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$45.52M$778.91M$5.47B$20.52BDividend YieldN/A4.84%5.25%3.78%P/E Ratio-1.881.0926.9627.79Price / SalesN/A230.52430.2040.48Price / CashN/A23.4436.8222.26Price / BookN/A6.137.984.58Net Income-$7.79M-$27.85M$3.16B$982.91M7 Day Performance-15.18%0.67%2.39%0.41%1 Month Performance-18.18%8.48%2.18%3.59%1 Year PerformanceN/A6.72%33.82%14.47% OS Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OSTXOS Therapies2.7831 of 5 stars$1.62-6.4%$18.00+1,011.1%N/A$48.61MN/A-1.88N/ACRDFCardiff Oncology1.6864 of 5 stars$3.15flat$9.88+213.5%+77.5%$209.57M$680K-3.4220News CoverageAnalyst ForecastMDWDMediWound1.619 of 5 stars$19.37+0.6%$31.80+64.2%+0.1%$209.39M$20.22M-9.2780EPRXEupraxia Pharmaceuticals2.3829 of 5 stars$5.76+8.7%$11.00+91.0%+123.6%$207.13MN/A-7.5829News CoverageGap UpHigh Trading VolumeSOPHSOPHiA GENETICS2.3499 of 5 stars$3.10+0.3%$7.00+125.8%-21.2%$206.74M$65.17M-3.10520News CoveragePositive NewsINBXInhibrx Biosciences0.9893 of 5 stars$14.27-1.1%N/A+46.5%$206.63M$200K0.12166News CoverageYMABY-mAbs Therapeutics3.2729 of 5 stars$4.51-4.0%$15.60+245.9%-62.7%$204.21M$87.68M-7.05150ACIUAC Immune2.7562 of 5 stars$2.03+1.0%$12.00+491.1%-40.5%$203.83M$28.30M-3.50140VORVor Biopharma3.9433 of 5 stars$1.62+52.8%$5.63+247.4%+164.9%$202.44MN/A-0.98140Options VolumeGap UpHigh Trading VolumeSCPHscPharmaceuticals4.1364 of 5 stars$3.81-1.6%$14.00+267.5%-9.4%$201.14M$41.98M-1.9930IMABI-Mab2.728 of 5 stars$2.42-5.8%$6.00+147.9%+41.0%$197.62M$3.89M0.00380Gap Up Related Companies and Tools Related Companies Cardiff Oncology Competitors MediWound Competitors Eupraxia Pharmaceuticals Competitors SOPHiA GENETICS Competitors Inhibrx Biosciences Competitors Y-mAbs Therapeutics Competitors AC Immune Competitors Vor Biopharma Competitors scPharmaceuticals Competitors I-Mab Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OSTX) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
